BioSpace News Archive

Over a period of time, the surface of our teeth tends to get layered with stains and dental plaques. A thorough cleaning of the teeth is essential to keep them clean and free from disease-causing bacteria.

Microalbuminuria is a condition that affects the kidney and restricts in retaining serum albumin, which is considered as a vital factor for the kidney to maintain its overall health of the body.

Oxehealth have announced that the company has secured financial commitments totalling £10m, which will be delivered in two rounds across 2021 and 2022.

Asensus Surgical , Inc. (formerly TransEnterix, Inc.) (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™, today announced the formal completion of its previously announced name and ticker symbol change.

Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that the United States Food and Drug Administration (FDA) has granted orphan drug designation to SIG-007 for the treatment of Fabry disease, a progressive, life-threatening lysosomal disease.

AVROBIO, Inc., a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 61,500 shares of the company’s common stock to five new employees as inducement awards under the company’s 2019 Inducement Plan.

Cutera, Inc. (NASDAQ: CUTR), a leading provider of laser and other energy-based aesthetic systems for practitioners worldwide, today announced the pricing of $125 million aggregate principal amount of 2.25% convertible senior notes due 2026 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).

Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that it will host a key opinion leader (“KOL”) webinar on the hyperhidrosis (excessive sweating) market on Friday, March 26, 2021 at 10:00 am EDT.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to report it has decided to expand Part B of its TACTI-002 Phase II trial, under the study’s Simon’s two- stage clinical trial design

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that its Chairman and Chief Executive Officer Ming Hsieh, Chief Financial Officer Paul Kim, and Chief Commercial Officer Brandon Perthuis are scheduled to virtually participate in the Oppenheimer 31st Annual Healthcare Conference